Return to Search
EN
Pulmonary embolism (PE) manifests in mild, moderate, and severe forms. Treatment strategies focus on resolving the blood clot through medication (thrombolysis), mechanical fragmentation via a catheter, or surgical removal.
In cases of mild pulmonary embolism, anticoagulant medications (blood thinners) are typically sufficient. Patients with a low risk of complications may sometimes be managed on an outpatient basis.
Severe pulmonary embolism involves the obstruction of both main pulmonary arteries, leading to acute circulatory shock, impaired circulation, and oxygen deprivation. Such critical patients receive intensive care. Fibrinolytic drug therapies, designed to dissolve obstructing clots, are administered in acute, shock-presenting cases. In severe scenarios, surgical embolectomy, a procedure rarely performed by cardiovascular surgeons to remove clots, may also be considered. The specific treatment plan is determined by physicians after a thorough evaluation of the patient's risk factors.
Anticoagulant therapies, including Heparin, are vital in managing PE. These medications prevent blood clotting and the formation of new clots but do not dissolve existing vascular obstructions. The potency of anticoagulants varies, necessitating regular laboratory monitoring.
While medications primarily prevent new clot formation, the body possesses its own natural fibrinolytic mechanism to dissolve existing clots. This intrinsic process typically activates within the first 24 hours, initiating the breakdown of established clots.
Pulmonary Embolism Treatment
In cases of mild pulmonary embolism, anticoagulant medications (blood thinners) are typically sufficient. Patients with a low risk of complications may sometimes be managed on an outpatient basis.
Severe pulmonary embolism involves the obstruction of both main pulmonary arteries, leading to acute circulatory shock, impaired circulation, and oxygen deprivation. Such critical patients receive intensive care. Fibrinolytic drug therapies, designed to dissolve obstructing clots, are administered in acute, shock-presenting cases. In severe scenarios, surgical embolectomy, a procedure rarely performed by cardiovascular surgeons to remove clots, may also be considered. The specific treatment plan is determined by physicians after a thorough evaluation of the patient's risk factors.
Anticoagulant therapies, including Heparin, are vital in managing PE. These medications prevent blood clotting and the formation of new clots but do not dissolve existing vascular obstructions. The potency of anticoagulants varies, necessitating regular laboratory monitoring.
While medications primarily prevent new clot formation, the body possesses its own natural fibrinolytic mechanism to dissolve existing clots. This intrinsic process typically activates within the first 24 hours, initiating the breakdown of established clots.